Neurocrine Biosciences (NBIX) Misses Q4 EPS by 11c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $146.23 -3.69%
Revenue Growth %: +30.8%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +30.8%
Financial Fact:
Income (loss) from operations: -38.44M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.07, $0.11 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $94.52 million versus the consensus estimate of $87.77 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lumentum shares rise on analyst upgrades, AI demand outlook
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
